🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Success Rates of Expectant vs. Medical Management for Retained Products After First-Trimester Abortion: Randomized Controlled Trial

RecruitingNAAges 18 Years - 45 YearsFemaleYael Yagur
NCT07534982 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This prospective randomized controlled trial evaluates the success of medical versus expectant management for retained products of conception (RPOC) following medical abortion with mifepristone and misoprostol for delayed miscarriage in the first trimester. Women aged 18-45 with sonographic evidence of RPOC (endometrial thickness \>10 mm with Doppler flow) will be randomized into two groups: medical management with misoprostol or expectant management (observation only). Follow-up will include ultrasound evaluations over six weeks to monitor uterine clearance and determine further interventions. Population: 150 participants, with 75 in each group. Inclusion Criteria: Stable women with RPOC after medical abortion, bleeding comparable to menstrual flow, and no fever. Exclusion Criteria: Hemodynamic instability, excessive bleeding, fever, or specific endometrial thickness criteria. Outcom

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 18-45. 2. RPOC identified on ultrasound after medical abortion, defined as endometrial thickness \>10 mm with Doppler flow into the uterine cavity. 3. Hemodynamically stable women with bleeding comparable to menstrual flow, without fever. Exclusion Criteria: 1. Hemodynamic instability, excessive bleeding, or fever. 2. Endometrial thickness \>40 mm. 3. Endometrial thickness \<10 mm without Doppler flow into the cavity. 4. Presence of a gestational sac within the uterine cavity. 5. Women who received two doses of misoprostol before evaluation.
💊

What it tests

  • medical management with misoprostol
📍

Where

1 site
Meir Medical Center
Kfar Saba, Israel
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy